Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

global access

EU flag

EMA announces launch of two advice pilots to improve clinical trials in Europe

The pilots are part of the Accelerating Clinical Trials in the EU initiative to foster high-quality clinical research

- PMLiVE

Eli Lilly’s Alzheimer’s drug unanimously endorsed by FDA panel of experts

The company is seeking approval of donanemab to treat patients with early stages of the disease

- PMLiVE

Ipsen and Marengo expand oncology research partnership in deal worth $1.2bn

The new agreement centres around Marengo’s TriSTAR T-cell engager platform

- PMLiVE

Almirall’s Klisyri receives expanded FDA approval to treat actinic keratosis

The precancerous condition is responsible for an estimated 60% of all squamous cell carcinoma cases

- PMLiVE

Moderna shares positive late-stage results for COVID-19/flu combination vaccine

The combined vaccine approach could simplify immunisation practices and lead to higher uptake

- PMLiVE

Researchers identify new major cause of inflammatory bowel disease

Crohn’s disease and ulcerative colitis affected more than 500,000 people in the UK in 2022

- PMLiVE

Roche’s ALK inhibitor Alecensa granted EC approval to treat early-stage lung cancer

Non-small cell lung cancer represents up to 85% of all lung cancer diagnoses

- PMLiVE

GSK’s RSV vaccine Arexvy approved by FDA for use in adults aged 50 to 59 years

The decision comes just over a year after the FDA approved Arexvy for use in adults aged 60 years and older

- PMLiVE

Tiziana shares promising results for intranasal foralumab in secondary progressive MS

The neurological disease is estimated to affect 2.8 million people globally

- PMLiVE

Mental health in the workplace – the vital role of good people management

By Rebecca Hall

- PMLiVE

Engaging with HCPs – are you optimising your remote and in-person communications?

By Lorraine Walters

- PMLiVE

FDA approves Geron’s Rytelo to treat lower-risk myelodysplastic syndrome patients

The oligonucleotide telomerase inhibitor is administered as an intravenous infusion every four weeks

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links